132
Participants
Start Date
March 31, 2006
Primary Completion Date
August 31, 2011
Study Completion Date
August 31, 2011
Bevacizumab (Avastin®)
15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity
Docetaxel (Taxotere®)
75 mg/m\^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
Oxaliplatin (Eloxatin®)
85 mg/m\^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
Sanofi-Aventis Administrative Office, Bridgewater
Lead Sponsor
Sanofi
INDUSTRY